bevacizumab,trifluridine tipiracil
roche,otsuka,taiho pharma
[]
new data from sunlight reported at #gi23: patients with previously treated mcrpc receiving ftd/tpi + bevacizumab experienced extended os compared to those receiving ftd/tpi (10.8 mo vs 7.5 mo) with no new safety signals observed. what's coming next for bevacizumab in mcrpc? 